Informed Consent
Item
written informed consent form
boolean
C0021430 (UMLS CUI [1])
Postmenopausal state | Breast Carcinoma Removed | Neoplasm Metastasis Absent | Adjuvant therapy Completed | Tamoxifen | Toremifene
Item
postmenopausal patients who had had a histologically or cytologically confirmed breast cancer removed at the time of diagnosis with no evidence of metastases and who had completed over 5 years of adjuvant therapy with tamoxifen or toremifen before entering the study
boolean
C0232970 (UMLS CUI [1])
C0678222 (UMLS CUI [2,1])
C0849355 (UMLS CUI [2,2])
C0027627 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0677850 (UMLS CUI [4,1])
C0205197 (UMLS CUI [4,2])
C0039286 (UMLS CUI [5])
C0076836 (UMLS CUI [6])
Age Amenorrhea | Age Postmenopausal state
Item
age ≥50 years with cessation of menses and age ＜50 years postmenopausal status defined by one of the following:
boolean
C0001779 (UMLS CUI [1,1])
C0002453 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2,1])
C0232970 (UMLS CUI [2,2])
Follicle stimulating hormone measurement
Item
fsh level ＞ 30-40 iu/l
boolean
C0202022 (UMLS CUI [1])
Amenorrhea Duration
Item
cessation of menses over the past 1 year
boolean
C0002453 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Amenorrhea Due to Chemotherapy | Amenorrhea Due to Luteinizing Hormone-releasing Hormone Agonist | Amenorrhea Due to Ovarian ablation Surgical
Item
are/become amenorrheic due to either chemotherapy or lhrh, are/become amenorrheic due to surgical ovarian ablation
boolean
C0002453 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0002453 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C1518041 (UMLS CUI [2,3])
C0002453 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0677922 (UMLS CUI [3,3])
C0543467 (UMLS CUI [3,4])
Estrogen receptor positive tumor | Progesterone receptor positive tumor | estrogen receptor status unknown | progesterone receptor status unknown
Item
the tumor was to be er and/or pgr-positive or the receptor status could have been unknown
boolean
C1562312 (UMLS CUI [1])
C1562928 (UMLS CUI [2])
C0279758 (UMLS CUI [3])
C0279768 (UMLS CUI [4])
Disease recurrence Evidence
Item
no evidence of recurrence of the disease at entry
boolean
C0679254 (UMLS CUI [1,1])
C3887511 (UMLS CUI [1,2])
Patient Available Follow-up
Item
patient must be accessible for follow-up
boolean
C0030705 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C3274571 (UMLS CUI [1,3])
Hormone receptor negative neoplasm Primary
Item
those patients known to have had receptor-negative primary tumors
boolean
C2584453 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
Malignant Neoplasms
Item
any concurrent malignancy
boolean
C0006826 (UMLS CUI [1])
Hormone replacement therapy | Adjuvant therapy | Tamoxifen | Toremifene
Item
patients who previously received hormone replacement therapy (hrt) during 5 years of adjuvant therapy with tamoxifen or toremifen
boolean
C0282402 (UMLS CUI [1])
C0677850 (UMLS CUI [2])
C0039286 (UMLS CUI [3])
C0076836 (UMLS CUI [4])
Aromatase Inhibitors | Chemotherapy
Item
patients who are currently receiving other aromatase inhibitors, or chemotherapy
boolean
C0593802 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
Cardiovascular Disease Serious | Liver disease Serious | Abnormal cardiovascular function Daily Significant | Liver function Abnormal Daily Significant | Laboratory Results Abnormal
Item
patients who have serious cardiovascular or hepatic disease with significantly abnormal daily function and/or laboratory results
boolean
C0007222 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C0232090 (UMLS CUI [3,1])
C0332173 (UMLS CUI [3,2])
C0750502 (UMLS CUI [3,3])
C0232741 (UMLS CUI [4,1])
C0205161 (UMLS CUI [4,2])
C0332173 (UMLS CUI [4,3])
C0750502 (UMLS CUI [4,4])
C1254595 (UMLS CUI [5,1])
C0205161 (UMLS CUI [5,2])
Life Expectancy
Item
life expectancy ＜ 12 months
boolean
C0023671 (UMLS CUI [1])